Categories
Politics

Democrats file ethics criticism towards Cruz, Hawley

Sens. Ted Cruz, R-Texas, right, and Josh Hawley, R-Mo., Attend the Senate Justice Committee Markup for Judicial Officer Nominations and Modernization Act in the Dirksen Building on Thursday, December 10, 2020 Online content policy.

Tom Williams | CQ Appeal, Inc. | Getty Images

Seven Democratic Senators filed a formal complaint Thursday calling on the Senate Ethics Committee to investigate GOP Sens. Ted Cruz and Josh Hawley’s efforts to discard the presidential election results.

The complaint comes more than two weeks after the deadly January 6 riot in the U.S. Capitol, led by supporters of former President Donald Trump.

“Senators Ted Cruz and Josh Hawley legitimized President Trump’s false statements about electoral fraud by announcing that they would object to the certification of voters on January 6,” the Senators wrote in a letter to the chairmen of the Senate Ethics Committee, Chris Coons, D-Del. and James Lankford, R-Okla.

Cruz, a Republican from Texas, signed a written objection to the confirmation of Arizona’s votes at the beginning of the joint session to count the January 6th election, which sparked debate in both houses. Then pro-Trump rioters stormed the Capitol and lawmakers evacuated.

After the Capitol was secured and lawmakers resumed sitting, Cruz and Hawley, along with other Senate Republicans, voted against the Arizona Electoral College results, despite others who had objected after the fatal attack voted for certification to vote.

Hawley, of Missouri, also continued his previously announced plan to sign a written objection to the Pennsylvania election. Cruz and Hawley voted against the adoption of the Pennsylvania election results.

“By continuing to object to the voters after the violent attack, Senators Cruz and Hawley gave legitimacy to the mob’s cause and made future violence more likely,” the senators said in the letter.

The letter was signed by Sens. Sheldon Whitehouse from Rhode Island, Ron Wyden from Oregon, Tina Smith from Minnesota, Richard Blumenthal from Connecticut, Mazie Hirono from Hawaii, Tim Kaine from Virginia, and Sherrod Brown from Ohio.

In the letter, Senators called on Coons and Lankford to investigate whether Cruz and Hawley’s actions constitute “inappropriate conduct” or otherwise violate the Senate Code of Ethics.

Hawley said in a statement released Thursday in response to the complaint: “Joe Biden and the Democrats are talking about unity but brazenly trying to silence dissent. This latest effort is a blatant abuse of the Senate’s ethics process and a blatant attempt to demand it. ” Partisan revenge. “

The Cruz, Coons and Lankford offices did not immediately respond to CNBC’s requests for comment.

Following the Capitol riot, Cruz and Hawley made statements condemning the violence.

“The attack on the Capitol was a despicable act of terrorism and a shocking attack on our democratic system,” Cruz said in a January 7 press release.

“These acts of violence were criminal. They must be convicted,” Hawley said in a January 8 statement.

Hawley has been criticized after being seen saluting protesters with a raised fist outside the Capitol before the joint session began. The publisher Simon & Schuster announced on January 7th that it would no longer publish Hawley’s upcoming book, although the Senator has since found a new publisher.

Trump is facing a second impeachment trial in the Senate despite not being in office now. The democratically controlled house indicted Trump on January 13 of inciting the Capitol uprising.

The legislature has also requested other investigations into the uprising. The Democratic-run house sent a letter to FBI Director Chris Wray and other agency chiefs on Jan. 16 for information about the intelligence and security flaws that led to the breakup of the Capitol. On Thursday, House Inspectorate Carolyn Maloney, DN.Y., asked Wray to investigate the role of social media site Parler in the attack.

Five people were killed in the riot, including a Capitol police officer.

Categories
Entertainment

Elijah Moshinsky, Met Opera Director With Fanciful Contact, Dies at 75

His anti-picture-book concept with a strong set turned out to be more effective for the powerfully voiced, dramatically volatile Mr. Vickers. The production (which can be seen on video) and the performance of Mr. Vickers were triumphs and changed the general understanding of opera.

The next year Peter Hall, director of the National Theater in London, invited Mr. Moshinsky to direct a production of Thomas Bernhard’s play “The Force of Habit,” which Mr. Moshinsky described as a comedic parable in the BBC interview with a “group of circus performers.” tries to play Schubert’s “Forellen” quintet, but can’t. ” The production was a dismal failure and only lasted six performances.

But that same year, Mr. Moshinsky found his booth with an acclaimed production of Berg’s “Wozzeck” for the Adelaide Festival, presented by the Australian Opera (now Opera Australia). In the following years he directed more than 15 productions for the company, including “Boris Godunov”, “Werther”, “Dialogues des Carmélites” and “Don Carlos”. At the Royal Opera he presented remarkable productions of “Lohengrin”, “Tannhaüser” and “The Rake’s Progress” as well as some Verdi rarities, including “Stiffelio” and “Attila”.

Mr. Moshinsky met Ruth Dyttman in 1967 during a Melbourne Youth Theater production of Brecht’s “The Caucasian Chalk Circle”. He designed the sets; She was in the cast. They married in 1970. Ms. Dyttman, a lawyer, survived him along with their two sons Benjamin and Jonathan and his brothers Sam and Nathan.

Mr. Moshinsky was an active theater director and worked at the National Theater, the Royal Shakespeare Company, and other institutions. He has directed several productions for the BBC television series of Shakespeare’s plays, including “A Midsummer Night’s Dream” with a cast of Helen Mirren, Robert Lindsay and Nigel Davenport.

It was an enchanting production, wrote John O’Connor in a 1982 review for The Times, that “fully captured every important aspect of the play, from royal romp to hilarious comedy, from threatening rumblings in the woods to joyful celebrations.”

Categories
Business

Ford to spend $610 million to recall three million autos

A visitor walks past a Ford Escape Titanium at a car show last April.

Greg Baker | AFP | Getty Images

DETROIT – Ford Motor will recall 3 million older vehicles due to possible problems with their airbag inflators, costing the automaker an estimated $ 610 million.

The company confirmed the cost in a petition filed with the Securities and Exchange Commission Thursday after the closing bell. Ford stock fell into the red during after-business trading, down about 2%. The stock rose 6.2% on Thursday to $ 11.53 per share – its highest closing price since June 2018. Ford’s market capitalization is more than $ 45 billion.

In the filing, Ford said the expense will be treated as a special item as part of its earnings for the fourth quarter on February 4th. This means he has no impact on Ford’s adjusted earnings before interest and taxes or adjusted earnings per share – closely watched items from Wall Street.

The National Highway Traffic Safety Administration turned down a 2017 petition from Ford on Tuesday to avoid recalling the vehicles carrying the potentially dangerous airbags made by auto supplier Takata.

The affected vehicles range from model years 2006 to 2012. These include Ford Ranger (2007-2011), Fusion (2006-2012), Edge (2007-2010), Lincoln MKZ / Zephyr (2006-2012), MKX (2007-2010 )) and Mercury Milan (2006-2011) vehicles.

The recall will affect approximately 2.7 million vehicles in the U.S. and approximately 300,000 in Canada and other locations, the company said.

Takata airbag inflators have been a constant issue for automakers for years. The failure can cause airbag inflators to burst and potentially deadly metal objects to fly inside the vehicle. The problem has been linked to the deaths of at least 27 people worldwide and 18 in the US, according to Reuters. The more than 67 million inflators problem is the largest automobile recall in US history

Categories
World News

Intel (INTC) earnings This fall 2020

Bob Swan, then Interim Chief Executive Officer and Chief Financial Officer of Intel Corp., reacts during the inauguration of the company’s research and development facility in Bengaluru, India, on November 15, 2018.

Samyukta Lakshmi | Bloomberg | Getty Images

Pat Gelsinger, Intel’s new CEO, said Thursday that the company’s troubled 7-nanometer chip manufacturing technique is on track to make chips sold in 2023.

However, he warned that Intel is likely to be outsourcing more and more chips to outside foundries.

The remarks came in a earnings call with analysts covering the quarter ended last December. It’s the last full quarter under CEO Bob Swan before Gelsinger takes over on February 15.

Intel stock closed 6.46% on Thursday after the chipmaker reported earnings and sales that exceeded investor expectations and its own forecast, driven by strong PC sales. However, details of Intel’s earnings were released on financial cables minutes before trading closed. After that, Intel gave up its profits and the stock fell.

Here’s how Intel did it:

  • Earnings per share (EPS): Adjusted for $ 1.52 versus $ 1.10 expected based on refinitive consensus estimates.
  • Revenue: $ 20 billion versus $ 17.49 billion expected by refinitive consensus estimates.
  • forecast: Revenue for the first quarter of 2020 of $ 18.6 billion and earnings per share of $ 1.03.

“I am pleased with the progress made in the health and recovery of the 7 nanometer program,” said Gelsinger. “I am confident that the majority of our 2023 products will be manufactured in-house. Given the breadth of our portfolio, it is likely that we will expand the use of external foundries for certain technologies and products.”

Intel’s troubled 7-nanometer technology has weighed on the company as it struggled to match the advances made by Asian chipmakers in chip manufacturing. Intel has both designed and manufactured its processors in the past. Competitors like AMD today typically use outside foundries to manufacture their designs.

Intel’s latest chips use a 14-nanometer or 10-nanometer process, while competing chips made by outside foundries like TSMC and Samsung currently use a 5-nanometer process. A smaller process is better because more transistors can fit in the same chip, increasing performance and efficiency, and creating a superior processor.

In December, activist hedge fund Third Point and its CEO Dan Loeb said in a letter to Intel’s board that the lag behind competitors was a critical vulnerability. He said Intel has fallen behind Asian chip foundries and urged Intel’s board of directors to make various changes to the company, including considering whether to outsource chip production or divest parts of the business such as acquisitions.

Intel customers like Apple, Amazon, and Microsoft have developed their own processors or have signaled that they intend to.

In the quarter ended December, Intel announced that the strength of PC sales helped it exceed expectations. It has been said that 33% more PCs with Intel chips were sold than at the same time last year, especially laptops. PC sales have been strong over the past year as people who work from home or go to school try to update their computers.

Intel increased its cash dividend 5% to $ 1.39 per share. However, the forecasts for revenue, earnings per share and operating margin for the first quarter were all lower than last year.

Revenue for the Intel data center group, which sells chips to companies that operate servers, declined 16% year over year for the quarter ended December.

Mobileye, its self-driving auto technology subsidiary, posted a 39% increase in revenue for the quarter year over year, according to Intel. Mobileye is still a small part of Intel, however – it had sales of $ 967 million in 2020, while Intel’s PC group had sales of $ 40.1 billion over the year.

Gelsinger, who most recently was CEO of VMWare, has a technical background and started his career at Intel. He is expected to push Intel to become more competitive in terms of chip manufacturing. Intel announced that it began manufacturing 10-nanometer chips during the quarter and that production will continue to increase this quarter.

Categories
Health

Biden Inherits a Vaccine Provide Unlikely to Develop Earlier than April

As the Biden administration takes power with a pledge to tame the most dire public health crisis in a century, one pillar of its strategy is to significantly increase the supply of Covid-19 vaccines.

But federal health officials and corporate executives agree that it will be impossible to increase the immediate supply of vaccines before April because of lack of manufacturing capacity. The administration should first focus, experts say, on fixing the hodgepodge of state and local vaccination centers that has proved incapable of managing even the current flow of vaccines.

President Biden’s goal of one million shots a day for the next 100 days, they say, is too low and will arguably leave tens of millions of doses unused. Data collected by the Centers for Disease Control and Prevention suggests that the nation has already reached that milestone pace. About 1.1 million people received shots last Friday, after an average of 911,000 people a day received them on the previous two days.

That was true even though C.D.C. data indicates that states and localities are administering as few as 46 percent of the doses that the federal government is shipping to them. An efficient vaccination regimen could deliver millions more shots.

“I love that he set a goal, but a million doses a day?” said Dr. Paul A. Offit, the director of the Vaccine Education Center at Children’s Hospital of Philadelphia and a member of a federal vaccine advisory board.

“I think we can do better,” he said. “We are going to have to if we really want to get on top of this virus by, say, summer.”

The pace of vaccination is critical not just to curbing disease and death but also to heading off the impact of more infectious forms of the virus. The C.D.C. has warned that one variant, which is thought to be 50 percent more contagious, might become the dominant source of infection in the United States by March. Although public health experts are optimistic that the existing vaccines will be effective against that variant, known as B.1.1.7, it may drive up the infection rate if enough people remain unvaccinated.

The current vaccination effort, which has little central direction, has sown confusion and frustration. Some localities are complaining they are running out of doses while others have unused vials sitting on shelves.

Mr. Biden is asking Congress for $20 billion to vastly expand vaccination centers to include stadiums, pharmacies, doctors’ offices and mobile clinics. He also wants to hire 100,000 health care workers and to use federal disaster relief funds to reimburse states and local governments for vaccination costs.

Dr. Mark B. McClellan, the director of Duke University’s health policy center, said those moves should help clear the bottlenecks and “push the number beyond a million doses a day and probably significantly beyond.”

The nation’s vaccine supply in the first three months of the year is expected to substantially exceed what is needed to meet the administration’s goal. According to a senior administration official, Pfizer-BioNTech and Moderna have been ramping up and are now on track to deliver up to 18 million doses a week. Together, they have pledged to deliver 200 million doses by the end of March. A third vaccine maker, Johnson & Johnson, might also come through with more doses. If all of that supply were used, the nation could average well over two million shots a day.

Asked Thursday afternoon by a reporter if one million shots a day was enough, Mr. Biden said: “When I announced it, you all said it’s not possible. Come on, give me a break, man. It’s a good start.”

Covid-19 Vaccines ›

Answers to Your Vaccine Questions

If I live in the U.S., when can I get the vaccine?

While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.

When can I return to normal life after being vaccinated?

Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they’ll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But it’s also possible for people to spread the virus without even knowing they’re infected because they experience only mild symptoms or none at all. Scientists don’t yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.

If I’ve been vaccinated, do I still need to wear a mask?

Yes, but not forever. The two vaccines that will potentially get authorized this month clearly protect people from getting sick with Covid-19. But the clinical trials that delivered these results were not designed to determine whether vaccinated people could still spread the coronavirus without developing symptoms. That remains a possibility. We know that people who are naturally infected by the coronavirus can spread it while they’re not experiencing any cough or other symptoms. Researchers will be intensely studying this question as the vaccines roll out. In the meantime, even vaccinated people will need to think of themselves as possible spreaders.

Will it hurt? What are the side effects?

The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection won’t be any different from ones you’ve gotten before. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. But some of them have felt short-lived discomfort, including aches and flu-like symptoms that typically last a day. It’s possible that people may need to plan to take a day off work or school after the second shot. While these experiences aren’t pleasant, they are a good sign: they are the result of your own immune system encountering the vaccine and mounting a potent response that will provide long-lasting immunity.

Will mRNA vaccines change my genes?

No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

The administration is promising to purchase even more vaccine doses as they become available from the vaccine makers, and to use the Defense Production Act to spur production. But federal health officials and corporate executives said those were longer-term goals because the supply for the first three months of the year was essentially fixed.

The Trump administration invoked the Defense Production Act to force suppliers to prioritize orders from Pfizer, Moderna and other vaccine makers whose products are still in development. Health officials said it was unclear how the new administration could use the law beyond that to boost production.

One senior federal health official involved in the government’s vaccine efforts said that Operation Warp Speed, the Trump administration’s crash development program, had looked at all available manufacturing capacity domestically and globally and that there was little space left to negotiate at this point. The official said that if there had been more doses available to the government in the first quarter, they would have been purchased.

Experts generally agree that the federal government should be locking in purchases of as many doses as possible because no one knows yet how long the vaccines will protect against the coronavirus, whether booster shots will be required and what threats mutations of the virus could pose.

From April and thereafter, the supply outlook brightens. Pfizer and Moderna have each committed to supply another 100 million doses by the end of July, and the companies might be able to provide even more. A week ago, Pfizer and BioNTech, its German partner, increased their global production target to 2 billion doses for the year from 1.3 billion doses.

Pfizer has delayed deliveries to European countries while it retools its Belgium factory to expand production. But at the firm’s factory in Kalamazoo, Mich., which supplies doses for Americans, production has quickened since the federal government ordered suppliers to prioritize Pfizer’s needs. The unexpected discovery that efficient syringes could extract a sixth dose from its vials also upped Pfizer’s estimates.

Moderna has also raised its production targets for the year to 600 million doses, up from 500 million.

Johnson & Johnson is expected to announce results from its vaccine trial within days. If that vaccine proves effective, it could drastically speed up the pace of vaccinations because unlike Moderna’s and Pfizer-BioNTech’s vaccines, it requires only one dose. The company could apply for emergency use authorization from the Food and Drug Administration as soon as the end of the month. While its manufacturing has lagged, Johnson & Johnson is trying to catch up to the goals detailed in the federal contract it signed last year.

The firm is now expected to deliver anywhere from several million to 12 million doses by the end of February, and 10 million to 20 million more doses at the end of March or the first week in April, according to several people familiar with the firm’s manufacturing output. The first batch would be produced at its Dutch factory, and later batches at a factory in Baltimore operated by its manufacturing partner, Emergent BioSolutions.

But to deliver the second batch that quickly, federal regulators may have to agree to delay certain manufacturing reviews of the vaccine from the Baltimore plant, according to people familiar with the situation. Those discussions are now underway.

Johnson & Johnson is also in preliminary talks with Merck, a major American pharmaceutical company, about using its production lines, one of several ideas that federal health officials discussed with the Biden transition team. Federal officials are interested in boosting the nation’s vaccine-making power long-term, and Merck’s facilities may be among the few with remaining manufacturing capability.

But Dr. McClellan, who sits on Johnson & Johnson’s board of directors, said it would take months to adapt Merck’s factory to produce Johnson & Johnson’s vaccine. A senior administration official predicted that it could take until the end of the year.

Other vaccine makers may also come through by midyear. Novavax has worked to iron out what were recently dire manufacturing problems that delayed its clinical trials. Moncef Slaoui, the scientific head of the federal vaccine development program in the Trump administration, said in a recent interview that Novavax could apply for emergency use authorization in late April. The government has already ordered 110 million doses of the Novavax vaccine, to be delivered by the end of June, and Novavax has said it believes it can meet that target.

Mr. Biden has surrounded himself with new health officials assigned to getting vaccines from factories to recipients, including Dr. Bechara Choucair, the former Chicago health commissioner who is the White House’s vaccinations coordinator, and Tim Manning, a former top official at the Federal Emergency Management Agency who is now the supply coordinator. Dr. David Kessler, the former F.D.A. commissioner, will help lead the federal government’s vaccine development program at the Department of Health and Human Services, with special attention to manufacturing.

After both the Pfizer-BioNTech and Moderna vaccines proved to be highly effective in clinical trials late last year, the Trump administration considered whether to rethink its strategy of backing six different vaccine makers and instead throw all of its weight behind the proven producers. One senior administration official described “countless hours of debate” over the issue.

In the end, officials decided it was critical to keep aiming for a broad portfolio of vaccines, in part because no one has figured out which vaccines might work best for children or be most effective against emerging variants. They recommended that the Biden administration do the same.

Katie Thomas and Donald G. McNeil Jr. contributed reporting.

Categories
Business

A choose declines to power Amazon to renew internet hosting Parler.

A federal judge on Thursday declined to force Amazon to resume hosting the social networking app Parler on its cloud computing platform. This is not in the public interest.

Amazon kicked Parler, who had become a hangout for far-right conservatives, off its platform in the days following the January 6 riot at the Capitol. Parler then sued Amazon, accusing the tech giant of failing to adequately warn of the termination of its services, and asking the court to force Amazon to host the social network. Parler also argued in his complaint in the U.S. District Court for the Western Washington District that Amazon partnered with Twitter in violation of antitrust laws.

Amazon responded that Parler has not moderated the violent and red-hot content on its website sufficiently and has no choice but to act quickly. It has also been denied having any contact with Twitter on the matter.

The judge Barbara J. Rothstein ruled that Parler made “only weak and factually imprecise speculations” about the alleged collusion between Amazon and Twitter. It also noted that “there is no debate” that Amazon’s commitment to reinstating Parler now, before the social network could establish an effective content moderation system, “would result in the continued posting of abusive, violent content “prompted Amazon to start Parler in the first place. The court, she wrote, “specifically rejects” forcing Amazon to deliver this type of violent speech.

Judge Rothstein wrote that the riot in the Capitol was “a tragic reminder that inflammatory rhetoric – faster and easier than many of us would have hoped – can turn a legitimate protest into a violent uprising.”

Although the judge did not dismiss the case outright, she wrote that Parler “has not been able to show that it is likely that he will prevail on the matter”.

Jeffrey Wernick, Parler’s chief operating officer, said in a statement that the litigation is still in its early stages. “We remain confident that we will ultimately prevail in the main case,” he said.

Categories
Politics

Distinguished Attorneys Need Giuliani’s Legislation License Suspended Over Trump Work

Dozens of prominent lawyers have signed a formal complaint requesting the suspension of Rudolph W. Giuliani’s bar license – the latest and loudest in a series of calls to reprimand him for his actions as President Donald J. Trump’s personal attorney.

The lawyers said Mr Giuliani crossed ethical boundaries in helping Mr Trump prosecute false allegations of election fraud and then delivered an incendiary speech reiterating those claims just before the January 6 uprising at the Capitol.

A draft complaint to the New York Supreme Court Appeals Committee accuses Mr. Giuliani of knowingly making false allegations about the election and calls for an investigation into “conduct involving dishonesty, fraud, deception or misrepresentation in or outside the court” .

Demands for Mr. Giuliani to be disciplined have increased in the weeks since the uprising and are only increasing now after Mr. Trump stepped down. The latest complaint, signed by a non-partisan who-is-who of legal figures from New York and beyond, is possibly the most serious condemnation of Mr Giuliani’s conduct to date.

The list included former acting US attorney general Stuart M. Gerson, former US district judges H. Lee Sarokin and Fern M. Smith, and two former attorneys general, Scott Harshbarger of Massachusetts and Grant Woods of Arizona. The complaint was also signed by prosecutors working for the same United States law firm for the Southern District of New York that Mr. Giuliani ran in the 1980s, including Christine H. Chung.

Ms. Chung, a member of the steering committee of Lawyers Defending American Democracy, the organization that made the complaint, said the group had reviewed Mr. Giuliani’s work on behalf of Mr. Trump and that it was a “targeted campaign for the going.” with a lie about a stolen election from the American people. “

“This is a man who once ran the highest law enforcement agency in this nation and he knows what is fraud and what is not,” said Ms. Chung, who did not work for the US law firm during Mr. Giuliani’s tenure. She added, “It is forbidden for a lawyer to attack the rule of law and it is dangerous.”

Ms. Chung said that by Thursday afternoon, more than 500 people had signed the complaint, which anyone could sign on the Lawyers Defending American Democracy website, and that she expected “thousands” more to add their names.

The complaint seeking the suspension of Mr Giuliani’s admission to exercise his right during an investigation into his conduct is one of several complaints that have been lodged with the Board of Appeal. It comes a week after New York Senator Brad Hoylman, chairman of the judiciary committee, urged the state judicial system to begin the formal process of revoking Mr. Giuliani’s legal license.

It could take months or even years to conduct the investigation and determine an appropriate sentence, largely due to procedural hurdles and the complexity of Mr Giuliani’s case, said Stephen Gillers, a law professor at New York University and an expert in legal ethics.

Mr Gillers said he hoped the court would conduct a thorough investigation suspending Mr Giuliani’s license as Mr Giuliani used his reputation as a lawyer to spread false accounts.

“It is a privilege and an honor to be a New York attorney, and in investigating Giuliani and possibly sanctioning him for his behavior, the courts are reiterating that fact,” Gillers said.

Mr Giuliani, who did not respond to requests for comment, discussed the complaints about his behavior on his radio show last week.

“I’ve been a prosecutor all my life – I’m not stupid,” he said. “I don’t want to get in trouble. And personally, I have a great sense of ethics. I hate it when people attack my integrity. “

In the weeks since the insurrection, Mr Giuliani also redoubled his allegations of electoral fraud, arguing on conservative talk radio and social media that the masses indicting the Capitol were left-wing radicals who were involved in a conspiracy around him and To discredit Mr. Trump.

The numerous demands for disciplinary action underscore the extent to which Mr Giuliani’s reputation has grown since his years as Federal Prosecutor for Organized Crime and his two terms as Mayor of New York City, during which he advocated law enforcement and emphasized cleaning, has changed the streets.

At Mr Trump’s rally on Jan. 6, not long before a violent mob stormed the Capitol, Mr Giuliani called for a “trial by battle” to address his discredited allegations of electoral fraud.

“I am ready to maintain my reputation, the president is ready to strengthen his reputation because we will find crime there,” said Giuliani.

In the complaint, Mr Giuliani is accused of holding on to his false allegations of widespread electoral fraud only on January 16, thereby sacrificing his reputation.

“Other lawyers have met ethical obligations by withdrawing from representing Mr Trump and his campaign,” the complaint said. “Mr. Giuliani not only gave the company his stature and attorney status, but he also shows no inclination to stop lying.”

Earlier this week, a person close to Mr Trump said Mr Giuliani would not be part of Mr Trump’s defense during his second Senate impeachment trial.

Categories
Business

Saks Fifth CEO says luxurious retail is ‘consolation meals’ throughout pandemic

A pedestrian walks past the Saks Fifth Avenue Inc. women’s shop on Brookfield Place in New York, USA

Allison Joyce | Bloomberg | Getty Images

Marc Metrick, chief executive of Saks Fifth Avenue, said luxury retail was like “comfort food” to some shoppers during the Covid-19 pandemic.

“People were buying things at the height of the pandemic that had no absolute functional end-use, but they love fashion,” Metrick said Thursday during a virtual presentation at the National Retail Federation’s Big Show. “I think what we learned is this [consumers] Think of luxury as retail convenience food. … It was her way of feeling – it was something so much more and so much deeper than a pair of shoes. “

“Why else would you buy 110 millimeter pumps … from a luxury brand when you work at home and at Zoom all day?” he said. “You do it because you love fashion, and it’s your oreo cookie. It’s yours – something that makes you feel better.”

For Saks he added: “That was a proof of concept [that] Fashion will prevail. “

Luxury retailers like LVMH’s high-end department store chain Neiman Marcus and Tiffany reported a similar trend over the past year: wealthy shoppers looking to forego even more for themselves during troubled times. Many of these consumers have spent less money on travel and restaurants because so many social activities were curtailed during the health crisis, and instead called on more designer handbags, diamond rings and extravagant home decor.

Metrick said interest in Saks’ personal shopper service has also increased during the pandemic, partly for safety reasons but also because people are looking for activity.

“When you buy luxury products, you want the experience,” he said. “They don’t want it to be just a transaction.”

A store within a store called “Barneys at Saks” opened earlier this month on the fifth floor of the flagship store on Saks Fifth Avenue in New York City. The department store chain Barneys New York filed for bankruptcy in 2019, but the brand lives on at Saks. Another of these mini-stores is slated to open later this month in Greenwich, Connecticut.

“Business is still important,” said Metrick. “Especially for luxury it is the theater.”

Categories
Health

What we realized because the first U.S. case was confirmed

Schwester Dawn Duran verabreicht Jeremy Coran während des Ausbruchs der Coronavirus-Krankheit (COVID-19) am 12. Januar 2021 in Pasadena, Kalifornien, USA, eine Dosis des COVID-19-Impfstoffs von Moderna.

Mario Anzuoni | Reuters

Heute vor genau einem Jahr bestätigten die Zentren für die Kontrolle und Prävention von Krankheiten den ersten Fall eines neuen Coronavirus auf US-amerikanischem Boden, den Wissenschaftler damals 2019-nCoV anriefen.

Seitdem hat das Land nach Angaben der Johns Hopkins University mehr als 24 Millionen Fälle und mehr als 400.000 Todesfälle verzeichnet. Ein neuer Präsident tritt sein Amt an und warnt davor, dass sich die Pandemie verschlimmern wird, bevor sie sich bessert.

Experten für öffentliche Gesundheit, Ärzte, Wissenschaftler und Führungskräfte aus Industrie und Regierung sagen jedoch, dass uns das vergangene Jahr viel über das Virus beigebracht hat – und wie diese Lehren angewendet werden können, um die Pandemie jetzt zu verlangsamen.

Ihre Erkenntnisse reichten von Erkenntnissen über das Virus selbst und dessen Ausbreitung – erinnern Sie sich, als wir alle unsere Lebensmittel mit Clorox abwischten? – Überlegungen zu unserem eigenen Verhalten und wie es uns zu immer höheren Infektionsraten verurteilt.

Einige, von dem ehemaligen Mitglied des Nationalen Sicherheitsrates, Dr. Luciana Borio, und dem Chef der Operation Warp Speed, Moncef Slaoui, betonen, wie wichtig es ist, frühzeitig mit der Industrie zusammenzuarbeiten. Andere sagen, das vergangene Jahr beweise, dass das Versprechen unserer biomedizinischen Technologien schnell verwirklicht werden kann – wenn sie nur gut genug finanziert sind.

Hier sind ihre Gedanken.

Auf den Virus

“Es ist nicht das Winter-Atemwegsvirus, für das es in Rechnung gestellt wurde”, sagte Dr. Paul Offit vom Kinderkrankenhaus in Philadelphia. “Es ist weitaus weitreichender und schädlicher als das.”

Vorhersagen im Frühjahr über den Verlauf des Virus warnten davor, dass es den Mustern der Influenzapandemie von 1918 ähneln könnte: eine mildere erste Welle, gefolgt von einer viel tödlicheren zweiten im Herbst.

Der Herbst 2020 brachte letztendlich eine befürchtete größere Welle von Coronavirus-Fällen mit sich, aber es war nicht wie ursprünglich erwartet nach einem einheitlichen Tiefpunkt durch den Sommer. Mitte Juli erreichte ein Höhepunkt mit etwa 76.000 Fällen, als das Virus über Florida, Texas und Arizona verbreitet wurde.

Zu diesem Zeitpunkt hatten Wissenschaftler bereits einen Überblick darüber, was dieses Virus so schädlich macht, sagten Experten, da sich die Erkenntnisse in den ersten Monaten rasant entwickelten.

“Anfang Januar letzten Jahres wurde uns mitgeteilt, dass es keine Übertragung von Mensch zu Mensch gibt”, sagte Dr. Megan Ranney von der Brown University. “Als wir merkten, dass es sich ausbreitete [person-to-person]Wir dachten, es würde sich wie eine Grippe ausbreiten … wir dachten, wir müssten uns Sorgen um Tröpfchen und Fomiten machen. “

Das hat sich geändert, sagte Ranney, “als wir diese erste schreckliche nordöstliche Welle überstanden haben.”

Die Tatsache, dass die Übertragung “mehr in der Luft ist als ursprünglich angenommen, weniger oberflächlich als ursprünglich angenommen”, hat wichtige “Auswirkungen auf Präventionsempfehlungen”, sagte Dr. Carlos del Rio von der Emory University. Daher: Masken und Vermeidung großer Versammlungen in Innenräumen.

Wissenschaftler haben aber auch gelernt, dass dieses Virus schwieriger ist als andere. Die Tatsache, dass es einige tödlich trifft, während andere stillschweigend infiziert werden, macht es tatsächlich so gefährlich, sagte Dr. Jeremy Faust vom Brigham and Women’s Hospital in Boston.

“Asymptomatische Übertragung hat einerseits gute Nachrichten: Nicht jeder wird so krank, wie wir dachten”, sagte Faust. “Andererseits ist es so viel schwieriger zu kontrollieren, weil die Leute denken: ‘Wenn es mir gut geht, geht es mir gut. Ich darf keine Gefahr für mich selbst oder andere sein.'”

Dr. Leana Wen, ehemalige Gesundheitskommissarin von Baltimore, sagte, dass die Denkweise den größten Teil der Verbreitung ausmacht, wenn wir durchschnittlich fast 200.000 Fälle pro Tag aufzeichnen.

“Es gibt immer noch ein gewisses Maß an magischem Denken, wenn es um Menschen geht, die wir kennen und lieben und die nicht in unserem Haushalt sind”, sagte sie. “Wir denken, ‘Nun, diese Person sieht gut aus; ich kenne sie, ich vertraue ihnen, dass sie sich nicht auf risikoreiche Verhaltensweisen einlassen würden, also werde ich sie sehen.'”

Da Menschen ohne Symptome so viel Ausbreitung verursachen können – laut CDC mehr als die Hälfte -, ist es am besten, “jeden so zu betrachten, als ob er ein Coronavirus haben könnte”, sagte Wen.

Über menschliches Verhalten

“Wir haben das Gefühl einer sich verändernden Grundlinie entwickelt”, sagte Dr. Michael Osterholm von der University of Minnesota. Im April, sagte er, fühlte es sich an, als ob das “Haus in Flammen stand”, wobei jeden Tag 32.000 Fälle gemeldet wurden. Bis Mai waren es nur noch etwa 20.000. “Die Leute hatten das Gefühl, wir hätten die Kurve abgeflacht, wir waren fertig”, sagte er.

Bis Mitte Juli erreichte dieser Anstieg durch den Sonnengürtel einen bisher unergründlichen neuen Höchststand von mehr als 70.000 Fällen pro Tag. Anfang September fielen die Fälle auf 26.000 zurück, eine Zahl, die “fast so hoch war wie das Hoch im April, aber die Leute meinten:” Sehen Sie, das ist gut, es ist unter Kontrolle “, sagte Osterholm.

Im Oktober begann der obere Mittlere Westen mit einer Infektion zu leuchten, und “zu Thanksgiving hatten wir fast 200.000 Fälle pro Tag”, sagte er. Auf dem jüngsten Höhepunkt des Landes, dem 8. Januar, wurden an einem einzigen Tag mehr als 300.000 Fälle gemeldet.

“Denken Sie an 300.000 gegenüber 32.000”, sagte Osterholm. “In einem Zeitraum von April bis Januar wurden wir taub dafür. Jeder von ihnen ist eine sich verändernde Grundlinie, und plötzlich scheint das, was geschah, nicht mehr so ​​schlimm zu sein.”

Es sei Teil der menschlichen Verfassung, auf diese Weise zu reagieren, um “ein Gefühl des Überlebens zu entwickeln”. Aber es ist eine zentrale Herausforderung, das Blatt in der Pandemie zu wenden.

Auch, so Osterholm und Ranney, befassen sich mit den strukturellen Problemen, die die Hauptlast der Pandemie auf die Armen, Verletzlichen und Farbigen ausüben.

“Wenn wir Strategien für die öffentliche Gesundheit entwickeln oder umsetzen, um eine Epidemie zu bekämpfen, sei es struktureller Rassismus, wirtschaftliche Ungleichheit, Trennung zwischen Ländern mit hohem und niedrigem Einkommen, wenn wir nicht auf die Treiber des Verhaltens der Menschen achten, werden wir scheitern.” Sagte Ranney. “Auch mit guter Wissenschaft.”

Borio, der zusammen mit Osterholm als Covid-19-Berater für den Biden-Übergang fungierte, bezeichnete die Bedeutung der Führung als das wichtigste Lernen aus dem vergangenen Jahr.

“Es muss oben beginnen”, sagte sie. “Eine geteilte Nation kann eine Pandemie nicht bekämpfen. Unsere Regierung, riesig und komplex, verfügt über enorme Fähigkeiten, organisiert sich aber nicht selbst.”

Aber halten Sie die Politik so weit wie möglich davon ab, fügte Slaoui hinzu, der letzte Woche als Chefberater der Operation Warp Speed ​​zurückgetreten war, der Trump-Administration, die sich bemühte, Impfstoffe und Medikamente für Covid-19 zu entwickeln.

“Wir dürfen Fragen der öffentlichen Gesundheit nie wieder politisieren”, sagte Slaoui. “Ich bin sicher, das hat Zehntausende Menschenleben gekostet.”

Über Regierung und Industrie

Sowohl Slaoui als auch Borio sowie der frühere FDA-Kommissar Dr. Scott Gottlieb, der auch CNBC-Mitarbeiter und Vorstandsmitglied von Pfizer und Illumina ist, sagten, das erste Jahr der Pandemie habe gezeigt, wie wichtig öffentlich-private Partnerschaften sind und wie man auf sie einwirkt schnell.

“Die Weigerung von CDC, frühzeitig zu kommerziellen Labors und kommerziellen Testkits zu wechseln, hat uns für die frühe Verbreitung blind gemacht”, sagte Gottlieb.

Die Fähigkeit der USA, das Virus zu erkennen, wurde in den ersten Wochen durch einen Test der CDC beeinträchtigt, der sich als fehlerhaft herausstellte.

“Das Virus konnte tief in unseren Gemeinden verwurzelt werden”, fügte er hinzu. “Es war ein historischer Misserfolg.”

Borio wies auf die Bedeutung von Datensystemen hin, die von Palantir erstellt wurden, Gensequenzierungspartnerschaften mit Unternehmen wie Illumina, diagnostische Tests durch Quest und LabCorp sowie die Verteilung von Impfstoffen über CVS und Walgreens.

“Ein wirklich modernes öffentliches Gesundheitssystem erfordert eine öffentlich-private Partnerschaft”, sagte sie.

Borio betonte jedoch auch die Bedeutung der Strenge im Regulierungsprozess und die Gefahren einer “vorzeitigen Erteilung” der Genehmigung für den Notfall, “bevor Daten aus angemessenen und gut kontrollierten Studien vorliegen, wie sie für viele der Therapeutika aufgetreten sind”.

Insbesondere Hydroxychloroquin war ein blaues Auge für die Food and Drug Administration, die im Juni ihre Genehmigung zur Verwendung in Notfällen für Covid-19 widerrief, nachdem festgestellt wurde, dass es wahrscheinlich nicht wirksam ist.

Das, sagte Borio, “hilft den Patienten nicht.”

Slaoui, der die wissenschaftliche Entwicklung bei einer der größten öffentlich-privaten Partnerschaften in der Krankengeschichte durch Operation Warp Speed ​​beaufsichtigte, betonte auch die Notwendigkeit, bessere klinische Studien durchführen zu können. Er sagte an einigen Stellen im letzten Jahr, dass in den USA mehr als 400 Studien durchgeführt wurden, die meisten ohne Placebo-Kontrolle, was als Goldstandard für das Testen neuer Therapien gilt. Viele nahmen auch nur eine Handvoll Patienten auf.

“Das ist äußerst ineffizient und mit hohen Opportunitätskosten verbunden”, sagte Slaoui.

Auf Technologie

Was gut kontrollierte Studien jedoch bewiesen haben, war, dass “mRNA-Impfstoffe funktionieren”, sagte Ranney. “Die Tatsache, dass wir nicht nur einen, sondern zwei mRNA-Impfstoffe haben, die effektiv beim Menschen eingesetzt wurden und sowohl sicher als auch wirksam bei der Vorbeugung der Krankheit sind, ist einfach riesig.”

Laut Borio wären sie jedoch nicht möglich gewesen, “ohne frühzeitige Investitionen der US-Regierung vor vielen Jahren; die Entwicklung dieser Technologien dauert Jahre.”

Sie nannte sie die “aufregendste Innovation in der Impfstofftechnologie seit Jahrzehnten”.

Der Ausbruch bewies auch die Geschwindigkeit und Nützlichkeit einer zweiten Technologie, Impfstoffe, die harmlose Viren verwenden, um genetisches Material vom Coronavirus zu den Körperzellen zu befördern, um eine Immunantwort auszulösen, sagte Slaoui. “Es gibt mindestens zwei sehr schnelle Impfstoffplattformen, mit denen Impfstoffe in Monaten entwickelt werden können”, fügte er hinzu.

“Was wir vermisst haben”, sagte er, “sind Produktionskapazitäten und -fähigkeiten.”

Slaoui sagte, die Antwort sei etwas, das er als Biopräparationsorganisation bezeichnet habe, die neue Impfstoffe gegen neu auftretende Bedrohungen entwickeln und sofort Hilfe leisten könne, wenn diese Bedrohungen eintreten würden. Er brachte die Idee zum ersten Mal im Jahr 2016 auf, als er Vorsitzender der Impfstoffe bei GlaxoSmithKline war, und sagte, sie habe sich nicht durchgesetzt, “aber wir müssen sie jetzt wiederbeleben.”

Borio zitierte die Ernennung von Eric Lander zum besten Wissenschaftsberater von Biden in einer neu erhöhten Position auf Kabinettsebene als Signal für eine neue Ära, in der die Wissenschaft “ein wesentlicher Bestandteil des politischen Entscheidungsprozesses sein wird”.

Offit, ein Experte für Impfwissenschaft, drückte es ganz klar aus: “Wir haben es in uns, einen Impfstoff sehr schnell herzustellen und zu testen”, sagte er, “wenn wir bereit sind, das Geld auszugeben.”

Vorausschauen

Trotz der Lehren aus dem ersten Jahr der Covid-19-Pandemie warnten Experten des öffentlichen Gesundheitswesens vor einem schwierigen Weg nach vorne.

“Was mir am meisten auffällt, ist, wie viel wir noch nicht wissen”, sagte Dr. Kayvon Modjarrad, Direktor der Abteilung für neu auftretende Infektionskrankheiten am Walter Reed Army Institute of Research.

Fragen wie: Wie verhält sich dieses Virus anders als andere Atemwegsviren? Wie entwickelt es sich? Warum verursacht es bei einigen so schwere Krankheiten, bei anderen jedoch asymptomatisch?

“In der Wissenschaft besteht der erste große Schritt zur Lösung eines der Rätsel der Natur darin, zu verstehen, wie groß das Rätsel ist und welche Fragen zu stellen sind”, sagte Modjarrad. “Wir erreichen diesen Punkt erst jetzt.”

Eine der dringendsten Herausforderungen besteht darin, dass eine als B.1.1.7 bekannte Variante, die als übertragbarer angesehen wird als frühere Formen des Coronavirus, wahrscheinlich “in den nächsten Wochen bis Monaten abheben wird”, sagte Osterholm. Das heißt: “Wir konnten die schlimmsten Tage der Pandemie vor uns sehen, selbst mit dem Impfstoff.”

Zu den dringendsten Aufgaben der Biden-Regierung gehört die Verwaltung der Verteilung von Coronavirus-Impfstoffen, für die ein Ziel von 100 Millionen Dosen festgelegt wurde, die in den ersten 100 Tagen verabreicht wurden.

Osterholm stellte jedoch fest, dass in diesem Tempo – selbst wenn ein zusätzlicher Impfstoff für die Verwendung freigegeben wird, für den nur eine Dosis erforderlich ist, wie Johnson & Johnson’s in den nächsten Monaten erwartet wird – nur etwa 14% der US-Bevölkerung vollständig von geimpft würden Ende April.

Zusammen mit geschätzten 30% der Bevölkerung, die bereits infiziert sind und möglicherweise Immunität haben, ist dies weniger als die Hälfte des Landes, das bis in den Mai hinein geschützt ist, “weit entfernt von jeglicher Herdenimmunität”, sagte Osterholm.

“Impfstoffe spielen keine Rolle, nur Impfungen”, fügte Modjarrad hinzu, Direktor der Abteilung für neu auftretende Infektionskrankheiten am Walter Reed Army Institute of Research. “Wir können uns nicht zu viel gratulieren oder zu früh den Sieg erklären.”

Dr. Anthony Fauci, der landesweit führende Wissenschaftler für Infektionskrankheiten, sagte diese Woche, er erwarte, dass das Land 75 bis 80% seiner durch den Herbst geimpften Bevölkerung erreichen könne.

“Wenn wir das von April, Mai, Juni, Juli, August an effizient tun”, sagte er den Gastgebern eines Livestreams von Harvard Business Review, “sollten wir bis zum Beginn des Herbstes das Maß an Schutz haben, das wir haben.” Ich denke, wir können zu einer Form der Normalität zurückkehren. “

Categories
Business

From ‘unloved’ to ‘favourite,’ Britain’s inventory market rides a wave.

The start of 2021 was rocky for the UK. Leaving the European Union sparked enormous bureaucracy that has desperately sought help from some industries, and the country is once again in lockdown due to a rapidly spreading strain of the coronavirus.

But there was a glimmer of hope. In the UK, more than four million people have been partially vaccinated against the coronavirus, a promising rate of vaccination.

Investors seeking a wave of optimism about vaccine rollouts have turned to the UK stock market, which had a strong start to the year, rising more than 6 percent in the first week.

In the first two and a half weeks of January, the FTSE 100, the UK’s benchmark index for large companies, rose 4.3 percent, outperforming the S&P 500 index, which was up 2.6 percent, and the Stoxx Europe 600 index, which was up 3 percent. Even when the profits are converted into US dollars, the FTSE 100 still has a clear head start.

In addition to the introduction of vaccines to help secure an economic recovery, another factor is attracting investors: the relative cheapness of UK stocks.

The UK FTSE 100 index benefits from an investment strategy in which traders buy so-called value stocks. These are companies that are believed to be trading below their real value because their business has been disrupted by a recession, particularly in the financial and energy sectors, and the FTSE 100 has a large stake in these stocks.

Citigroup analysts have made the UK stock market their “preferred” stock market.

“I would like to stress that the very unloved and terribly horrific UK market might be worth a look this year,” said Robert Buckland, a Citigroup equity strategist, in a presentation last week. “We all know it’s been a place to avoid for many, many years.”

Updated

Jan. 21, 2021, 8:46 ET

The UK stock market has been lagging behind for years. The last time the FTSE’s earnings looked better than the US and European benchmarks was in 2016, when a sharp fall in the pound boosted the profits of the FTSE 100 companies, which have three-quarters of their sales overseas.

When converted to US dollars, the FTSE 100’s annual return was the worst of the three indices over the past nine years.

Why are investors now betting on a trend reversal? For one, a lot of them are ready for a bargain. The bull market for stocks has been dominated by expensive stocks in American tech companies, which makes some investors nervous about how much they can go further. An alternative is cheap stocks in industries that tend to do well in times of economic recovery.

And then there is the UK’s free trade agreement with the European Union. Some investors put aside the details of whether it was a good deal or a bad deal to make it easier for an agreement to finally be reached in late December.

The deal “reduced the uncertainty of the overhang people,” said Caroline Simmons, the UK’s chief investment officer at UBS Global Wealth Management. And it could encourage the return of foreign investors who were deterred by Brexit, she said. Up until last week, the Swiss asset management company stated for the first time since 2013 that UK stocks were among its most preferred deals.

Two Schroders wealth managers in London are hoping that interest in large companies will return to smaller companies that are lagging behind. Rory Bateman and Tim Creed raised £ 75 million ($ 102 million) in December for their British Opportunities Trust, a fund that will invest in public and private companies that are affected by the pandemic but that they expect to be they recover with a little more capital.

The vaccines were the “beginning of the mood reversal in Britain,” Bateman said. “The momentum is definitely shifting.”

However, this strategy depends heavily on the success of the vaccine launch and can easily be reversed by signs of delays in manufacture or distribution. And the UK stock index could fall back to the bottom of the stack.